ImmunityBio appeared to be the type of small-cap biotech story that quickly attracts believers at one point in early 2026. The FDA approved ANKTIVA. An independent committee deemed the QUILT-2.005 trial to be sufficiently powered and fully enrolled because of how well it was reading out. The bank received a $100 million capital raise, reducing the funding overhang that plagues most businesses at this point. The founder, Patrick Soon-Shiong, was doing what he usually does, which is to speak in public frequently and with an almost evangelistic confidence. The tone of the story completely changed after the FDA sent a letter.
The Office of Prescription Drug Promotion issued the warning, which was centered on two messages: a television commercial and an appearance on The Sean Spicer Show podcast in January. The agency objected to claims that ANKTIVA could “treat all cancers” or serve as a recurrence-prevention vaccine. In actuality, the medication is only permitted in conjunction with BCG for a particular group of patients with bladder cancer. It is an exact indication. The vocabulary surrounding it was anything but.
| ImmunityBio, Inc. — Key Information | Details |
|---|---|
| Company Name | ImmunityBio, Inc. |
| Ticker Symbol | IBRX (NASDAQ) |
| Founder & Executive Chairman | Patrick Soon-Shiong |
| Headquarters | Culver City, California |
| Lead Product | ANKTIVA (nogapendekin alfa inbakicept-pmln) |
| Approved Indication | BCG-unresponsive non-muscle invasive bladder cancer |
| Recent FDA Action | Warning letter from Office of Prescription Drug Promotion, late March 2026 |
| Key Trial Update | QUILT-2.005 fully enrolled; supplemental BLA planned late 2026 |
| Recent Capital Raise | $100 million ($75M non-dilutive from Oberland Capital, $25M debt conversion from Nant Capital) |
| Intraday Stock Reaction | Fell as much as 30% after warning letter — biggest single-day move in 15 months |
| Analyst Narrative Fair Value | $13.50 (implying ~91% upside before the warning) |
| Pending Legal Risk | Multiple securities class action filings tied to ANKTIVA promotion |
The events that followed seemed almost staged. The sharpest intraday decline in fifteen months occurred when shares fell as much as thirty percent in a single session. Class action lawsuits in the securities industry started to surface, claiming that investors had been duped by the same advertising claims that are currently being investigated by the federal government. The podcast was removed from ImmunityBio’s website. Soon after, Shiong returned to Spicer’s program and attempted to thread a needle by claiming that the TV commercial “never aired at all” and that regulators had only seen a transcript submitted through standard review channels. That might be technically correct. Additionally, investors rarely accept this kind of clarification.
All of this has an odd tension to it. Soon-Shiong has presented the warning letter as a conflict between scientific discourse and what the FDA considers to be promotional communication, thereby framing it as a free speech issue. He sort of has a point. In a media environment where podcast appearances now reach audiences larger than primetime cable used to, it is truly difficult to distinguish between explaining a drug’s science and marketing its use.
However, the specific quotes mentioned in the letter were not subtle, and the FDA’s regulations on this matter are not new. Declaring that a treatment “can treat all cancers” is not a legal gray area. This is the type of statement that compliance officers highlight in red.
The story is more complicated because of the larger context. The FDA itself has been in apparent disarray; Commissioner Marty Makary reportedly faced complaints brought to the White House by officials, including Health Secretary Robert F. Kennedy Jr., and a division chief resigned amid allegations of abusing federal authority. As of right now, the agency appears to be in disarray at the top. It appears that some traders are interpreting this volatility as a possible opening, speculating that a distracted or reorganized FDA might proceed more quickly with label expansions. Although it’s a thin thesis, thin theses are what move stocks in this market.
The science isn’t really what investors are left to consider. The clinical narrative of ANKTIVA remains unchanged. The actual swing factors for the company’s long-term value are still represented by the QUILT-2.005 data and the impending supplemental BLA. The credibility layer, which is the portion of the investment case that relies on management’s ability to negotiate the tight passageways regulators create around approved medications, has changed. A clean regulatory path was assumed in the narrative that projected $1.2 billion in revenue by 2029. There is now an asterisk next to that assumption.
The speed at which momentum stocks like this one can flip is difficult to ignore. After a single letter, podcast, or collection of quotes is included in a federal filing, the topic of discussion shifts from a 91% upside to class action exposure and label expansion risk. The FDA’s response to ImmunityBio’s compliance promises, the success of the class actions, and whether the QUILT-2.005 readout in late 2026 gives the bulls something tangible to point to once more will all determine whether that is an overreaction or a fair repricing. For the time being, the stock is in that awkward middle ground between real science, real product, and real concerns about the storytellers.